As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

German Consumer Sentiment Sinks on Income Expectations; EUR/USD Holds LossesWed, 26 Feb 2025 11:03:15 GMT Dow Jones: Nvidia’s Strong Results Power Tech Stocks as Tariff Worries PersistThu, 27 ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Merck KGaA has patented substituted bicyclic transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TED interaction inhibitors reported to be useful for the treatment of ...

Walgreens had used Everly's physician network to order COVID-19 tests that customers requested ... 2025 Healthcare & Pharmaceuticalscategory Merck prevails in US safety litigation over Gardasil ...

In this piece, we will look at the stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer recalled the stock market crash due to the coronavirus.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...